PATRICK DEVAL L - 14 Jun 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 14 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2022, 16:46:00 UTC
Prior SEC filing: 15 Jun 2022
Next SEC filing: 17 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Mark Bodenrader, as Attorney-in-Fact

Key filing fact

PATRICK DEVAL L filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 16 Jun 2022.

Key facts

This page summarizes PATRICK DEVAL L's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2022, 16:46.

Change

Previous filing in this sequence was filed on 15 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CERE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,459
Change %
Price: $0.000000
Shares after: 23,459
Date: 14 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,459
Exercise price: $24.35
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.

SEC remarks

Exhibit 24 - Power of Attorney